Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
NCT ID: NCT06331572
Last Updated: 2024-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
162 participants
OBSERVATIONAL
2021-08-01
2023-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi-factor Model Constraction for Early Warning and Diagnosis of MDD
NCT05529576
Objective Diagnostic Markers and Personalized Intervention in MDD Patients
NCT02023567
Optimization of Diagnosis and Treatment of Depression Based on Multidimensional Clinical Assessment Classification
NCT04528628
Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
NCT03219008
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
NCT03537794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TRD
1. age 12-18 years
2. Meet the diagnostic criteria for MDD according to the DSM-5
3. HAMD-17 score \> 13
4. currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms \<50%)
17-HAMD
Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
FEDN-MDD
1\. age 12-18 years 2. Meet the diagnostic criteria for MDD according to the DSM-5 2. First-episode and drug-naive 4. HAMD-17 score \> 17
17-HAMD
Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
HC
1. age 12-18 years
2. HAMD-17 score \< 7
3. HCs without a personal history of a mental illness or family history in a first-degree relative
17-HAMD
Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
17-HAMD
Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age 12-18 years
2. Meet the diagnostic criteria for MDD according to the DSM-5
3. First-episode and drug-naive
4. HAMD-17 score \> 17
TRD:
1. Age 12-18 years
2. Meet the diagnostic criteria for MDD according to the DSM-5
3. HAMD-17 score \> 13
4. Currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms \<50%)
HC:
1. age 12-18 years
2. HAMD-17 score \< 7
3. HCs without a personal history of a mental illness or family history in a first-degree relative
Exclusion Criteria
1. the presence or past history of severe medical, neurological or psychiatric disorders (other than MDD in patients)
2. anxiety comorbidity was not considered an exclusion criterion provided that MDD was the main diagnosis and the primary reason for seeking assistance
3. substance abuse, head trauma, or loss of consciousness
4. Chronic physical diseases that significantly affect peripheral metabolism or neurological function
5. Pregnant and lactating women
HC:
1. the presence or past history of severe medical, neurological or psychiatric disorders
2. substance abuse, head trauma, or loss of consciousness
3. Chronic physical diseases that significantly affect peripheral metabolism or neurological function
4. Pregnant and lactating women
12 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Chongqing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xinyu Zhou
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Province, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1stChongqingMU-TRD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.